Walleye Capital’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-44,372
Closed -$1.62M – 6058
2026
Q2
$1.62M Buy
+44,372
New +$1.4M 0.01% 1710
2026
Q1
– Sell
-141,769
Closed -$5.3M – 4651
2025
Q4
$5.3M Buy
+141,769
New +$4.66M 0.02% 1115
2023
Q3
– Sell
-196,200
Closed -$6.9M – 5059
2023
Q2
$6.9M Buy
196,200
+155,656
+384% +$5.37M 0.03% 567
2023
Q1
$1.32M Buy
+40,544
New +$1.85M 0.02% 973

Other funds holding HRMY

Walleye Capital's HRMY Position: Q3 2026 in Review

Walleye Capital sold out of Harmony Biosciences (HRMY) in Q3 2026, closing a stake of 44,372 shares — an estimated $1.62M sold.

Walleye Capital first reported a position in HRMY in Q1 2023 and held it in 4 quarters. The position peaked at $6.9M in Q2 2023. 353 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Walleye Capital reported no remaining Harmony Biosciences position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 44,372 Harmony Biosciences shares in Q3 2026, an estimated $1.62M.
  • Walleye Capital first reported a position in Harmony Biosciences in Q1 2023 and held it in 4 quarters.
  • Walleye Capital's Harmony Biosciences position peaked at $6.9M in Q2 2023.
  • 353 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.